Understanding how cells change their fate and how to control this process
Multiscale tools and approaches for understanding and engineering cell-fate transitions
This study is looking at how we can change the way cells behave to help improve treatments for cancer and help with healing, so that patients can benefit from better therapies that target their specific needs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10894872 on NIH RePORTER |
What this research studies
This research focuses on synthetic biology to explore how cells can be engineered to change their fate, which is crucial for applications like cancer treatment and regenerative medicine. By developing multiscale tools, the project aims to understand the complex mechanisms that regulate gene expression and cell behavior. The approach involves studying various biological processes, from molecular interactions to cell signaling, to improve the effectiveness of cellular therapies. Patients may benefit from advancements in targeted therapies that can better control cell behavior and fate.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with conditions that could benefit from advanced cellular therapies, such as cancer or degenerative diseases.
Not a fit: Patients with stable conditions that do not require innovative cellular therapies may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cancer and other diseases by improving how we can control cell behavior.
How similar studies have performed: Previous research in synthetic biology has shown promising results in manipulating cell fate, indicating that this approach has potential for success.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Galloway, Kate Elizabeth — Massachusetts Institute of Technology
- Study coordinator: Galloway, Kate Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.